Charles River Laboratories (CRL) Tops Q2 EPS by 2c; Lowers Outlook
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $186.60 +2.78%
EPS Growth %: -12.5%
Financial Fact:
Selling, general and administrative: 85.65M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -12.5%
Financial Fact:
Selling, general and administrative: 85.65M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.77, $0.02 better than the analyst estimate of $2.75. Revenue for the quarter came in at $973.1 million versus the consensus estimate of $997.96 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $10.70-$10.95, versus the consensus of $11.53. Sees revenue up 9-11% versus prior of 13.5-15.5%.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- Green Dot and CommerceOne shareholders approve acquisition deal
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
